Darunavir . ethanolate

• Background :

  Darunavir ethanolate is a highly potent HIV protease inhibitor (IC50=3-6nM, depending on laboratory HIV-1 strain), an antiretroviral medication used to treat and prevent HIV/AIDS. The ethanolate formulation has some stability advantages compared to the free base Darunavir (Prod. No. AG-CR1-3712) . Darunavir ethanolate is a second generation HIV-1 protease inhibitor that inhibits replication of various laboratory strains and clinical isolates of HIV-1, including those resistant to first generation protease inhibitors. It inhibits cell-free diffusion and cell-to-cell spread of HIV-1 in Jurkat cell populations. Formulations containing darunavir have been used in combination therapy for the treatment of HIV. Shown in a SARS-CoV-2 protease structure model study to potentially bind and inhibit the papain like viral protease (PLVP) of SARS-CoV-2, responsible for COVID-19.

• Type :

  Chemical

• Purity :

  Greater than or equal to 98% (HPLC)

• Shipping Conditions :

  Room Temp

• Storage Conditions :

  Short Term Storage: +4C. Long Term Storage: -20C. Handling Advice: Keep cool and dry. Use/Stability: Stable for at least 2 years after receipt when stored at -20C.

• Calculated Molecular Weight :

  547.7 . 46.0

• Other Product Names :

  TMC114; TMC41629; UIC-94017; HSDB 7788; Prezista

• Physical Properties :

  Lyophilized

• CAS Number :

  635728-49-3